MRG004A Antibody
Based on 1 Customer Validation
MRG004A Antibody (HuSC1-39) is a monoclonal antibody inhibitor targeting tissue factor (TF). MRG004A Antibody can be used to synthesize the antibody-drug conjugate (ADC) MRG004A. MRG004A Antibody can be used to research related to cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 95.44%
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human
MRG004A Antibody activates the STING pathway via proteasome-dependent degradation of TREX1, leading to cytosolic micronuclei accumulation, increased STING pathway phosphorylation, and STING-dependent induction of CCL5 and CXCL10 mRNA in HPAF-II, BxPC3, MDA-231, and HCC1806 cells[1].
MRG004A Antibody (15 μg/mL; 24 h for cytokine secretion, 48 h for viability) increases CXCL10 and IFN?γ secretion and reduces tumor cell viability in HPAF-II, BxPC3, or MDA-231 cells co-cultured with PBMCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human PDAC HPAF-II, BxPC3 cells, human TNBC MDA-231 cells, PBMCs
-
Concentration:15 μg/mL (cytokine secretion); 15 μg/mL (tumor cell viability)
-
Incubation Time:24 h (cytokine secretion); 48 h (tumor cell viability)
-
Result:Increased secretion of CXCL10 and IFN-γ.
Reduced tumor cell viability.
MRG004A Antibody (10 mg/kg; i.v.) inhibits subcutaneous BxPC3 pancreatic ductal adenocarcinoma growth in nude mice, activates the STING innate immune pathway, reduces pro-tumor signaling, and depletes TREX1 protein levels[1].
MRG004A Antibody (10 mg/kg; i.v.) inhibits subcutaneous HPAF-II pancreatic ductal adenocarcinoma growth in nude mice, activates the STING innate immune pathway, reduces pro-tumor signaling, and depletes TREX1 protein levels[1].
MRG004A Antibody (10 mg/kg; i.v.) inhibits subcutaneous HCC1806 triple-negative breast cancer growth in nude mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice[1]
-
Dosage:10 mg/kg
-
Administration:i.v.
-
Result:Inhibited tumor growth.
Reduced TF, P-ERK, and P-AKT relative intensity in tumor sections.
Increased P-STING and P-TBK1 relative intensity in tumor sections.
Nearly eliminated TREX1 protein staining in tumor tissue.\nInhibited tumor growth.
Reduced TF, P-ERK, and P-AKT relative intensity in tumor sections.
Increased P-STING and P-TBK1 relative intensity in tumor sections.
Nearly eliminated TREX1 protein staining in tumor tissue.
-
Animal Model:Nude mice[1]
-
Dosage:10 mg/kg
-
Administration:i.v.
-
Result:Inhibited tumor growth.
F3/Factor III/Tissue Factor/CD142
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized Tissue Factor-hFc can bind MRG004A Antibody. The EC50 for this effect is 102.6 ng/mL.
化学情報
-
性状 Liquid
-
Color Colorless to light yellow
-
SMILES
[MRG004A Antibody]
-
別名
HuSC1-39
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
MRG004A Antibody 関連分類
HY-P991989 関連分類
Powered by Bioz